Skip to Main Content

++

INTRODUCTION

++

fosfomycin (fos-foe-mye-sin)

Monurol

Classification

Therapeutic: anti-infectives

Pharmacologic: phosphonic acid derivatives

++
Indications
++

Uncomplicated urinary tract infections in women (acute cystitis).

++
Action
++

Inactivates an enzyme crucial for bacterial cell wall synthesis. Decreases adherence of bacteria to uroepithelial cells. Therapeutic Effects: Bactericidal action against susceptible bacteria. Spectrum: Active against Enterococcus faecalis and Escherichia coli.

++
Adverse Reactions/Side Effects
++

CNS: dizziness, headache, weakness. GI: PSEUDOMEMBRANOUS COLITIS, diarrhea, dyspepsia, nausea. GU: vaginitis.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Be alert for signs of pseudomembranous colitis, including diarrhea, abdominal pain, fever, pus or mucus in stools, or other severe or prolonged GI problems (nausea, cramps, vomiting). Notify physician immediately if these signs occur.

  • Assess dizziness and weakness that might affect gait, balance, and other functional activities (See Appendix C). Report balance problems and functional limitations to the physician and nursing staff, and caution the patient and family/caregivers to guard against falls and trauma.

++
Interventions
++

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Employ universal precautions or isolation procedures as indicated for specific patients.

++
Patient/Client-Related Instruction
++

  • Instruct patient to report other bothersome side effects such as severe or prolonged headache, vaginal irritation, or GI problems (nausea, diarrhea, indigestion).

++
Pharmacokinetics
++

Absorption: Rapidly absorbed and converted to fosfomycin, its active component, resulting in 37% bioavailability.

++

Distribution: Distributes to kidneys and bladder wall; crosses the placenta.

++

Metabolism and Excretion: Excreted unchanged in urine (38%) and feces (18%).

++

Half-life: 5.7 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (bactericidal urine levels*)

ROUTE ONSET PEAK DURATION
PO rapid 2–4 hr unknown

*Symptoms may take 24–48 hr to subside.

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity; Pyelonephritis; Lactation: Lactation.

++

Use Cautiously in: OB/Pedi: Pregnancy or children <12 yr (safety not established).

++
Interactions
++

Drug-Drug: Urinary excretion and blood levels are ↓ by metoclopramide.

++
Route/Dosage
++

PO (Adults and Children ≥18 yr): 3 g single dose.

++
Availability
++

Sachet: 3 g.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.